3 assets in Infectious Mononucleosis

Therapeutic assets addressing Infectious Mononucleosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Bendamustine Infectious Mononucleosis	Yale University	P2	CCC (53)
Brentuximab Vedotin Infectious Mononucleosis	Yale University	P2	CCC (53)
Rituximab Infectious Mononucleosis	Yale University	P2	CCC (53)